Publisher
Springer Science and Business Media LLC
Reference103 articles.
1. Burbige EJ, Huang SS, Bayless TM: Clinical manifestations of Crohn’s disease in children and adolescents. Pediatrics 1975, 55:866–871.
2. Gryboski J, Hillemeier C: Inflammatory bowel disease in children. Med Clin North Am 1980, 64:1185–1202.
3. Plevy SE, Taylor K, DeWoody KL, et al.: Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn’s disease patients with poor clinical responses to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997, 112:A1062. This subanalysis of the infliximab trial reported by Targan et al. [66] suggests that stratification of CD patients based on serum immune and genetic markers may ultimately allow patients to be treated more selectively with specific cytokinedirected therapies.
4. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, in press. The potential benefits of combining the patient’s TPMT genotype with thiopurine metabolite levels as a means of individualizing and optimizing 6-MP/AZA therapy are described in this study.
5. Vasiliauskas EA: Monoclonal antibody therapy in inflammatory bowel disease. In Inflammatory Bowel Diseases: Nestlé Nutrition Workshop Series Clinical & Performance Programme. Edited by Bistrian BR, Walker-Smith JA. Nestec Ltd., Vevey/S. Karger AG, Basel; 1999, 2:237–255. This article reviews the rationale and role of cytokine specific monoclonal antibody therapies directed against TNF-a in the treatment of IBD and discusses specific considerations relevant to the application of this form of therapy in patient care.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献